These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35112378)

  • 81. Generation of a high-fidelity antibody against nerve growth factor using library scanning mutagenesis and validation with structures of the initial and optimized Fab-antigen complexes.
    La Porte SL; Eigenbrot C; Ultsch M; Ho WH; Foletti D; Forgie A; Lindquist KC; Shelton DL; Pons J
    MAbs; 2014; 6(4):1059-68. PubMed ID: 24830649
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Potential mechanisms for hypoalgesia induced by anti-nerve growth factor immunoglobulin are identified using autoimmune nerve growth factor deprivation.
    Hoffman EM; Zhang Z; Anderson MB; Schechter R; Miller KE
    Neuroscience; 2011 Oct; 193():452-65. PubMed ID: 21802499
    [TBL] [Abstract][Full Text] [Related]  

  • 83. A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip or knee.
    Schnitzer TJ; Marks JA
    Osteoarthritis Cartilage; 2015 Jan; 23 Suppl 1():S8-17. PubMed ID: 25527221
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Low immunogenicity of tocilizumab in patients with rheumatoid arthritis.
    Burmester GR; Choy E; Kivitz A; Ogata A; Bao M; Nomura A; Lacey S; Pei J; Reiss W; Pethoe-Schramm A; Mallalieu NL; Wallace T; Michalska M; Birnboeck H; Stubenrauch K; Genovese MC
    Ann Rheum Dis; 2017 Jun; 76(6):1078-1085. PubMed ID: 28007755
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Population Pharmacokinetics and Exposure-Response Modeling of Golimumab in Adults With Moderately to Severely Active Ulcerative Colitis.
    Adedokun OJ; Xu Z; Liao S; Strauss R; Reinisch W; Feagan BG; Sandborn WJ
    Clin Ther; 2020 Jan; 42(1):157-174.e4. PubMed ID: 31982148
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Safety of Low-Dose Tanezumab in the Treatment of Hip or Knee Osteoarthritis: A Systemic Review and Meta-analysis of Randomized Phase III Clinical Trials.
    Yu Y; Lu ST; Sun JP; Zhou W
    Pain Med; 2021 Mar; 22(3):585-595. PubMed ID: 33141224
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Population Pharmacokinetics of Galcanezumab, an Anti-CGRP Antibody, Following Subcutaneous Dosing to Healthy Individuals and Patients With Migraine.
    Kielbasa W; Quinlan T
    J Clin Pharmacol; 2020 Feb; 60(2):229-239. PubMed ID: 31482569
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Analgesic effects of nerve growth factor-directed monoclonal antibody on diabetic neuralgia in an animal model.
    Dong X; Li H; Pei M; Tan J; Chen G; Li S; Xie Z; Wang Q; Wang G; Chen YL; Wang C
    FEBS Open Bio; 2022 Jul; 12(7):1325-1335. PubMed ID: 35417079
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
    Smith WB; Dowell JA; Pratt RD
    Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Targeting nerve growth factor to relieve pain from osteoarthritis: What can we expect?
    Berenbaum F
    Joint Bone Spine; 2019 Mar; 86(2):127-128. PubMed ID: 30266445
    [No Abstract]   [Full Text] [Related]  

  • 91. Pharmacokinetics and absolute bioavailability of mepolizumab following administration at subcutaneous and intramuscular sites.
    Ortega H; Yancey S; Cozens S
    Clin Pharmacol Drug Dev; 2014 Jan; 3(1):57-62. PubMed ID: 27128231
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Pharmacology of nerve growth factor and discovery of tanezumab, an anti-nerve growth factor antibody and pain therapeutic.
    Hefti F
    Pharmacol Res; 2020 Apr; 154():104240. PubMed ID: 31026504
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain.
    Schnitzer TJ; Lane NE; Birbara C; Smith MD; Simpson SL; Brown MT
    Osteoarthritis Cartilage; 2011 Jun; 19(6):639-46. PubMed ID: 21251985
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Understanding the Monoclonal Antibody Disposition after Subcutaneous Administration using a Minimal Physiologically based Pharmacokinetic Model.
    Varkhede N; Forrest ML
    J Pharm Pharm Sci; 2018; 21(1s):130s-148s. PubMed ID: 30011390
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous "manual syringe" injection or intravenously in women with HER2-positive early breast cancer.
    Quartino AL; Hillenbach C; Li J; Li H; Wada RD; Visich J; Li C; Heinzmann D; Jin JY; Lum BL
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):77-88. PubMed ID: 26645407
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn's Disease: Analyses of Phase I and II Trials.
    Suleiman AA; Khatri A; Minocha M; Othman AA
    Clin Pharmacokinet; 2019 Mar; 58(3):375-387. PubMed ID: 30123942
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration.
    Othman AA; Tran JQ; Tang MT; Dutta S
    Clin Pharmacokinet; 2014 Oct; 53(10):907-18. PubMed ID: 25212703
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Targeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists?
    Bannwarth B; Kostine M
    Drugs; 2014 Apr; 74(6):619-26. PubMed ID: 24691709
    [TBL] [Abstract][Full Text] [Related]  

  • 99. The lymphatic system plays a major role in the intravenous and subcutaneous pharmacokinetics of trastuzumab in rats.
    Dahlberg AM; Kaminskas LM; Smith A; Nicolazzo JA; Porter CJ; Bulitta JB; McIntosh MP
    Mol Pharm; 2014 Feb; 11(2):496-504. PubMed ID: 24350780
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Modification of the Fc Region of a Human Anti-oncostatin M Monoclonal Antibody for Higher Affinity to FcRn Receptor and Extension of Half-life in Cynomolgus Monkeys.
    Nnane IP; Han C; Jiao Q; Tam SH; Davis HM; Xu Z
    Basic Clin Pharmacol Toxicol; 2017 Jul; 121(1):13-21. PubMed ID: 28132416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.